How to treat NASH with targeting LSECs has been shown in a study that RUNX1 siRNA immunonano-lipocarrier tagged with VEGFR3 antibodies (specific marker of LSECs), specifically silenced the RUNX1 gene in LSECs and improved NASH inflammation (Ding et al., 2010; Tripathi et al., 2021). The gene discussed is FLT4; the disease is metabolic dysfunction-associated steatohepatitis.